What is Leerink Partnrs' Forecast for NAMS Q1 Earnings?

NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of NewAmsterdam Pharma in a report released on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings of ($0.20) per share for the quarter. The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma's Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.25) EPS, FY2026 earnings at ($1.15) EPS and FY2027 earnings at ($1.20) EPS.

NAMS has been the subject of a number of other reports. Piper Sandler reiterated an "overweight" rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Scotiabank raised their price target on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a "sector outperform" rating in a report on Wednesday, December 11th. Needham & Company LLC reiterated a "buy" rating and issued a $36.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $36.20.

NewAmsterdam Pharma Trading Up 0.2 %

NewAmsterdam Pharma stock traded up $0.04 during midday trading on Friday, reaching $25.50. 1,026,266 shares of the company's stock were exchanged, compared to its average volume of 378,655. The stock's 50-day simple moving average is $21.31 and its 200 day simple moving average is $18.95. NewAmsterdam Pharma has a 52 week low of $10.50 and a 52 week high of $27.29.

Insider Buying and Selling at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total value of $707,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Nap B.V. Forgrowth sold 100,728 shares of the business's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $26.10, for a total value of $2,629,000.80. Following the completion of the sale, the insider now owns 10,908,502 shares of the company's stock, valued at approximately $284,711,902.20. This trade represents a 0.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 353,542 shares of company stock valued at $8,599,328 in the last ninety days. 19.50% of the stock is currently owned by corporate insiders.

Institutional Trading of NewAmsterdam Pharma

Several large investors have recently modified their holdings of NAMS. Banque Cantonale Vaudoise acquired a new stake in shares of NewAmsterdam Pharma during the 2nd quarter worth approximately $38,000. Quarry LP lifted its stake in NewAmsterdam Pharma by 2,469.2% during the third quarter. Quarry LP now owns 6,500 shares of the company's stock worth $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC lifted its stake in NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company's stock worth $126,000 after purchasing an additional 7,199 shares during the last quarter. Bellevue Group AG acquired a new stake in shares of NewAmsterdam Pharma in the 3rd quarter valued at $128,000. Finally, XTX Topco Ltd bought a new position in shares of NewAmsterdam Pharma in the 3rd quarter valued at $187,000. 89.89% of the stock is owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.